Latest & greatest articles for risperidone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on risperidone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on risperidone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for risperidone

1. Risperidone

Risperidone Top results for risperidone - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box (...) and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for risperidone The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical

Trip Latest and Greatest2018

2. Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation).

Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation). BACKGROUND: Aggressive, agitated or violent behaviour due to psychosis constitutes an emergency psychiatric treatment where fast-acting interventions are required. Risperidone is a widely accessible antipsychotic that can be used to manage psychosis-induced aggression or agitation. OBJECTIVES: To examine whether oral risperidone alone is an effective treatment for psychosis-induced aggression or agitation (...) CRITERIA: Randomised controlled trials (RCTs) comparing rapid use of risperidone and other drugs, combinations of drugs or placebo for people exhibiting aggression or agitation (or both) thought to be due to psychosis. DATA COLLECTION AND ANALYSIS: We independently inspected all citations from searches, identified relevant abstracts, and independently extracted data from all included studies. For binary data we calculated risk ratio (RR) and for continuous data we calculated mean difference (MD), all

Cochrane2018

3. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial.

Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. BACKGROUND: Although predominant negative symptoms of schizophrenia can be severe enough to cause persistent impairment, effective treatment options are lacking. We aimed to assess the new generation antipsychotic cariprazine in adult patients with predominant negative symptoms. METHODS: In this randomised, double-blind, phase 3b (...) trial, we enrolled adults aged 18-65 years with long-term (>2 year), stable schizophrenia and predominant negative symptoms (>6 months) at 66 study centres (mainly hospitals and university clinics, with a small number of private practices) in 11 European countries. Patients were randomly assigned (1:1) by an interactive web response system to 26 weeks of monotherapy with fixed-dose oral cariprazine (3 mg, 4·5 mg [target dose], or 6 mg per day) or risperidone (3 mg, 4 mg [target dose], or 6 mg

Lancet2017

4. Comparison between the efficacies of Risperidone with Haloperidol in the treatment of attention-deficit hyperactivity disorder (ADHD) among preschoolers: a randomized double-blind clinical trial.

Comparison between the efficacies of Risperidone with Haloperidol in the treatment of attention-deficit hyperactivity disorder (ADHD) among preschoolers: a randomized double-blind clinical trial. 27790334 2016 10 28 2017 02 24 8 9 2016 Sep Electronic physician Electron Physician Comparison between the efficacies of Risperidone with Haloperidol in the treatment of attention-deficit hyperactivity disorder (ADHD) among preschoolers: a randomized double-blind clinical trial. 2840-2848 (...) Attention-deficit hyperactivity disorder (ADHD) is a common psychiatric disease with a worldwide pooled prevalence of 5.29%. To compare the efficacy of Risperidone with Haloperidol in the treatment of attention-deficit hyperactivity disorder (ADHD) among 3- to 6-year-old children. In a 6-week double-blind clinical trial, the efficacy of Risperidone 0.5-2 mg with a dose of maximum Haloperidol 0.075 mg/kg was assessed in 39 children aged 3-6 years. This study was conducted at the Golestan Psychiatric Clinic (Ahvaz, Iran). Measurement

Electronic physician2016 Full Text: Link to full Text with Trip Pro

5. Adjunctive aripiprazole in risperidone-induced hyperprolactinaemia: double-blind, randomised, placebo-controlled trial.

Adjunctive aripiprazole in risperidone-induced hyperprolactinaemia: double-blind, randomised, placebo-controlled trial. 27703744 2016 10 05 2017 02 20 1 2 2015 Oct BJPsych open BJPsych Open Adjunctive aripiprazole in risperidone-induced hyperprolactinaemia: double-blind, randomised, placebo-controlled trial. 172-177 Hyperprolactinaemia is a troublesome side-effect of treatment with antipsychotics. This double-blind, placebo-controlled study aimed at examining the effect of adjunctive treatment (...) with 10 mg aripiprazole on prolactin levels and sexual side-effects in patients with schizophrenia symptomatically maintained on risperidone. Thirty patients taking risperidone were enrolled into the trial (CTRI/2012/11/003114). Aripiprazole was administered at a fixed daily dose of 10 mg/day for 8 weeks. Serum prolactin was measured at baseline and at 8 weeks. Hyperprolactinaemia-related problems, psychopathology and side-effects were evaluated every 2 weeks. Prolactin levels decreased by 58

BJPsych open2016 Full Text: Link to full Text with Trip Pro

6. WITHDRAWN: Risperidone versus other atypical antipsychotic medication for schizophrenia.

WITHDRAWN: Risperidone versus other atypical antipsychotic medication for schizophrenia. BACKGROUND: Risperidone is one of a number of 'atypical antipsychotics' which are currently being marketed for the treatment of those with schizophrenia, largely on the basis of claims of improved tolerability and effectiveness compared to much cheaper conventional antipsychotics. The efficacy of risperidone has already been compared to conventional drugs, but it remains unclear how risperidone compares (...) with other atypical antipsychotic drugs such as clozapine. OBJECTIVES: To determine the effects of risperidone compared with other atypical antipsychotic drugs for schizophrenia. SEARCH METHODS: Electronic searches of Biological Abstracts (1980-1999), The Cochrane Library (Issue 1, 2000), The Cochrane Schizophrenia Group's Register (January 1999), EMBASE (1980-1999), MEDLINE (1966-1999), LILACS (1982-1999), PSYNDEX (1977-1999) and PsycLIT (1974-1999) were undertaken. In addition, pharmaceutical databases

Cochrane2016

7. Pharmacological interventions: Long-acting injectable risperidone as an option in first-episode psychosis

Pharmacological interventions: Long-acting injectable risperidone as an option in first-episode psychosis Long-acting injectable risperidone as an option in first-episode psychosis | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Long-acting injectable risperidone as an option in first-episode psychosis Article Text Electronic pages Pharmacological interventions Long-acting injectable risperidone as an option in first-episode psychosis Nancy H Covell Statistics from Altmetric.com No Altmetric data available for this article. ABSTRACT FROM: Subotnik

Evidence-Based Mental Health2016

8. Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction

Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone

Evidence-Based Mental Health2015

9. Risperdal (Risperidone) - schizophrenia and bipolar disorders and persistent aggression in conduct disorder in children and ersistent aggression in patients with moderate to severe Alzheimer's dementia

Risperdal (Risperidone) - schizophrenia and bipolar disorders and persistent aggression in conduct disorder in children and ersistent aggression in patients with moderate to severe Alzheimer's dementia

Haute Autorite de sante2014

10. Augmentation with cognitive behavioural therapy has superior efficacy to augmentation with risperidone for treating adults with treatment-resistant OCD

Augmentation with cognitive behavioural therapy has superior efficacy to augmentation with risperidone for treating adults with treatment-resistant OCD Augmentation with cognitive behavioural therapy has superior efficacy to augmentation with risperidone for treating adults with treatment-resistant OCD | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Augmentation with cognitive behavioural therapy has superior efficacy to augmentation with risperidone for treating adults with treatment-resistant OCD Article Text Psychological interventions

Evidence-Based Mental Health2014

11. Risperidone

Risperidone USE OF RISPERIDONE IN PREGNANCY 0344 892 0909 USE OF RISPERIDONE IN PREGNANCY (Date of issue: January 2015 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Risperidone is an atypical antipsychotic used in the treatment (...) of schizophrenia, mania, and for the short term management of persistent aggression. Although risperidone exposures are included in a number of studies which report on fetal outcome for cohorts of women exposed to various antipsychotics, the percentage and absolute number of risperidone exposures in each of these cohorts is generally very small and no separate analysis for risperidone was undertaken. The very limited data that are available for risperidone specifically do not provide evidence of an increased

UK Teratology Information Service2014

12. Is risperidone effective and safe for treating behavioral disturbances in elderly patients with dementia?

Is risperidone effective and safe for treating behavioral disturbances in elderly patients with dementia? Is risperidone effective and safe for treating behavioral disturbances in elderly patients with dementia? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Is risperidone effective and safe for treating behavioral (...) disturbances in elderly patients with dementia? View/ Open Date 2013-07 Format Metadata Abstract Risperidone improves behavioral disturbances of dementia, with superior tolerability to haloperidol. Unfortunately, use is associated with an increased incidence of cerebrovascular events and overall mortality. Nevertheless, it may still be reasonable to offer risperidone to patients with severe neuropsychiatric symptoms, after a discussion of the risks and benefits. URI Part of Part of Citation Evidence

Evidence Based Practice 2013

13. Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis

Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis Moteshafi H, Stip E CRD summary The authors concluded (...) of schizophrenia and affective disorders. Searching PubMed, EMBASE and PsycINFO were searched up to 2010 without language restrictions. Search terms were reported. ClinicalTrials.gov was searched. Reference lists of relevant articles were checked for further studies. Study selection Eligible studies were randomised controlled trials (RCTs) that compared side effects of four antipsychotics (quetiapine, risperidone, ziprasidone and aripiprazole) in the treatment of patients (aged 18 to 65 years

DARE.2013

14. Review: limited evidence that risperidone reduces aggression and conduct problems in the short term in children and adolescents with disruptive behaviour disorders

Review: limited evidence that risperidone reduces aggression and conduct problems in the short term in children and adolescents with disruptive behaviour disorders Review: limited evidence that risperidone reduces aggression and conduct problems in the short term in children and adolescents with disruptive behaviour disorders | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: limited evidence that risperidone reduces aggression and conduct problems in the short term in children and adolescents with disruptive behaviour disorders Article Text

Evidence-Based Mental Health2013

15. Risperidone and paliperidone: risk of intraoperative floppy iris syndrome in patients undergoing cataract surgery

Risperidone and paliperidone: risk of intraoperative floppy iris syndrome in patients undergoing cataract surgery Risperidone and paliperidone: risk of intraoperative floppy iris syndrome in patients undergoing cataract surgery Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search Risperidone and paliperidone: risk of intraoperative floppy iris syndrome in patients undergoing cataract surgery From: Published: 15 November 2013 Therapeutic area: , , , and Cases (...) of intraoperative floppy iris syndrome (IFIS) during cataract surgery have been reported in patients taking the atypical antipsychotics risperidone or paliperidone. Article date: November 2013 Intraoperative floppy iris syndrome (IFIS) is a complication observed during cataract surgery that was first described in 2005 in association with the α1-adrenergic antagonist tamsulosin. α1-adrenergic receptors are present in the iris dilator muscle of the eye, where inhibition of the receptors relaxes this muscle

MHRA Drug Safety Update2013

16. Long-acting risperidone increases medication costs and does not improve outcomes in unstable schizophrenia

Long-acting risperidone increases medication costs and does not improve outcomes in unstable schizophrenia Long-acting risperidone increases medication costs and does not improve outcomes in unstable schizophrenia | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Long-acting risperidone increases medication costs and does not improve outcomes in unstable schizophrenia Article Text Therapeutics Long-acting risperidone increases medication costs and does not improve outcomes in unstable schizophrenia Statistics from Altmetric.com No Altmetric data available

Evidence-Based Mental Health2013

18. Cost-effectiveness analysis of olanzapine and risperidone in Norway

Cost-effectiveness analysis of olanzapine and risperidone in Norway Cost-effectiveness analysis of olanzapine and risperidone in Norway Cost-effectiveness analysis of olanzapine and risperidone in Norway Kim K, Aas E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study (...) and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of two atypical antipsychotics, olanzapine and risperidone, for the treatment of schizophrenia. Due to the uncertainty in the results, the authors could not conclude that olanzapine was more cost-effective than risperidone, in Norway, but they stated that the model could be useful with more reliable trial data. The methods were robust and various areas of uncertainty were considered. The authors’ conclusions appear to be valid. Type

NHS Economic Evaluation Database.2012

19. Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden

Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia (...) -effectiveness of paliperidone palmitate for patients with schizophrenia, who had experienced two or more relapses (multi-episodes). Interventions Paliperidone palmitate long-acting injectable was compared with risperidone long-acting injectable and olanzapine pamoate long-acting injectable. Paliperidone was administered once a month, at a 75mg dose equivalent. Olanzapine was administered every two weeks at a 150mg dose, or every four weeks at a 300mg dose. Risperidone was administered every two weeks

NHS Economic Evaluation Database.2012

20. Review: risperidone, olanzapine and haloperidol are the most effective drugs for acute mania in adults with bipolar I disorder

Review: risperidone, olanzapine and haloperidol are the most effective drugs for acute mania in adults with bipolar I disorder Review: risperidone, olanzapine and haloperidol are the most effective drugs for acute mania in adults with bipolar I disorder | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: risperidone, olanzapine and haloperidol are the most effective drugs for acute mania in adults with bipolar I disorder Article Text Therapeutics Review: risperidone, olanzapine and haloperidol are the most effective drugs for acute mania

Evidence-Based Mental Health2012